ICU Medical (ICUI) Set to Announce Quarterly Earnings on Thursday

Key Points

• ICU Medical is expected to report Q3 2026 results on November 5 after the market closes, with analysts forecasting $2.14 in earnings per share and $552.07 million in revenue.
• The company exceeded expectations in its latest quarter, posting $2.37 EPS and $547.88 million in revenue, while year-over-year revenue increased 0.5%.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $192.80 price target, although insiders have sold approximately $3.9 million of stock over the past three months.

ICU Medical (NASDAQ:ICUI - Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect ICU Medical to announce earnings of $2.14 per share and revenue of $552.07 million for the quarter. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Investors may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business had revenue of $547.88 million for the quarter, compared to analysts' expectations of $533.44 million. During the same quarter in the prior year, the firm earned $2.10 earnings per share. The firm's revenue was up .5% on a year-over-year basis. On average, analysts expect ICU Medical to post $7.22 EPS for the current fiscal year and $8.05 EPS for the next fiscal year.

ICU Medical Trading Up 2.0%

NASDAQ ICUI opened at $166.39 on Thursday. The stock's 50-day simple moving average is $164.97 and its two-hundred day simple moving average is $148.75. ICU Medical has a twelve month low of $113.37 and a twelve month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of 141.01, a PEG ratio of 2.10 and a beta of 0.86.

Insider Activity at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 5,417 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christian Voigtlander sold 8,929 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer directly owned 37,377 shares of the company's stock, valued at $6,837,374.61. This represents a 19.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,830 shares of company stock valued at $3,905,003 over the last three months. Corporate insiders own 2.10% of the company's stock.

Analysts Set New Price Targets

ICUI has been the topic of a number of recent research reports. Zacks Research cut shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Needham & Company LLC boosted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a report on Friday, August 7th. BTIG Research upped their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, August 7th. KeyCorp increased their target price on shares of ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, ICU Medical presently has an average rating of "Moderate Buy" and a consensus price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.